Form 4: Outset Medical GC sells shares for tax cover

Outset Medical’s General Counsel sold 388 shares at $4.60 in a non-discretionary, sell-to-cover transaction tied to RSU vesting and now holds 46,495 shares.

Summary

• General Counsel John L. Brottem sold 388 shares of Outset Medical, Inc. (OM) on 11/17/2025 at $4.60 per share.
• Transaction code S indicates a sale; footnote clarifies it was a non-discretionary sell-to-cover for tax withholding.
• Sale related to the vesting of an aggregate 748 RSUs granted on 01/06/2023 and 01/12/2024.
• Post-transaction beneficial ownership stands at 46,495 shares, held directly.
• No derivative securities transactions were reported.
• No forward-looking statements, guidance, or strategic changes were disclosed.

Sentiment

Score: 6

Explanation: Routine, non-discretionary sell-to-cover with modest size and continued significant ownership; neutral to slightly positive from a governance and signaling standpoint.

Positives

• Sale was explicitly non-discretionary (sell-to-cover) for tax withholding, limiting signaling risk.
• RSU vesting of 748 shares indicates ongoing equity compensation and retention.
• Officer retains a sizable stake with 46,495 shares beneficially owned after the transaction.

Negatives

• Insider sale occurred on 11/17/2025 (388 shares at $4.60).
• Direct shareholdings decreased slightly due to tax-withholding sale.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Sale was required to cover tax withholding obligations upon RSU vesting and does not represent a discretionary trade.

Industry Context

Sell-to-cover transactions tied to RSU vesting are common across medtech and broader public companies, reflecting routine tax withholding mechanics rather than discretionary views on valuation.

Comparison to Industry Standards

• Non-discretionary sell-to-cover around RSU vesting aligns with standard executive compensation practices at medtech peers (e.g., Baxter, BD, Boston Scientific) and broader S&P 500 norms.
• Small transaction size relative to typical executive holdings is consistent with routine tax settlements rather than portfolio rebalancing or signaling activity.

Stakeholder Impact

• Minimal market impact expected given small, non-discretionary tax-withholding sale.
• Shareholders gain visibility into executive equity vesting and ongoing ownership levels.

Key Dates

Keywords

Outset Medical, OM, Form 4, insider transaction, sell to cover, RSU vesting, beneficial ownership, General Counsel, tax withholding, executive compensation